EU investigating Teva for blocking rivals to multiple sclerosis drug
"We do not believe that Teva adopted anti-competitive behaviors in relation to Copaxone," the company said in a statement. The EU competition enforcer, which had in November last year announced a preliminary investigation into the company, said the case was important because more than half a million Europeans needed treatment for multiple sclerosis.Reuters | Updated: 04-03-2021 17:36 IST | Created: 04-03-2021 17:36 IST
Israeli drugmaker Teva is being investigated by EU antitrust regulators who are looking into whether it illegally hindered rivals' access to its multiple sclerosis medicine Copaxone. The European Commission, which carried out unannounced inspections of Teva in 2019 and 2020, said the probe will look into whether Teva has abused its dominant market position in breach of EU antitrust rules, which could lead to hefty fines.